#Sweden #Stockholm #Lecanemab #BioArctic #Alzheimer's

BioArctic's Founder Awarded for Alzheimer's Breakthroughs

BioArctic AB, a pioneering biopharma company from Sweden, has formally announced that its founder, Professor Lars Lannfelt will be honored with the 2025 Hartwig Piepenbrock-DZNE Prize. This accolade is in recognition of his groundbreaking work regarding Alzheimer’s disease and his leading role in developing lecanemab, a promising therapeutic agent for patients affected by this condition. The prize ceremony will take place in Bonn in November, facilitated by the German Center for Neurodegenerative Diseases (DZNE) and the Piepenbrock Group, which aims to acknowledge exceptional contributions to neurodegenerative research.

Professor Lannfelt expressed his pride and gratitude on receiving this prestigious award, highlighting his unwavering commitment to enhancing the treatment landscape for Alzheimer’s disease patients. His research endeavors have ignited significant advancements in the field, particularly with the promising results achieved in the Phase 3 Clarity AD trial for lecanemab. The research has revealed substantial benefits for patients, making it a landmark moment in Alzheimer's treatments.

Lecanemab showcases the efficacy of modern medical science in combating Alzheimer's disease, especially considering its foundation on Lannfelt's earlier discoveries regarding the amyloid-beta protein's role in the disease progression. The antibody treatment, developed in collaboration with the Japanese pharmaceutical company Eisai, aims to specifically target amyloid-beta forms, facilitating their removal from the brain. This innovative approach embarks on reshaping Alzheimer’s treatment, and Lannfelt's vision sees future approaches that may not only slow down disease progression but possibly halt it.

Since its establishment in 2003, BioArctic has remained at the forefront of developing innovative treatments for neurodegenerative conditions. The company has expanded its research portfolio beyond Alzheimer's, venturing into other critical areas such as Parkinson’s disease and ALS. Lecanemab (also branded as Leqembi®) stands out as a monumental achievement for BioArctic, marking the first-ever drug confirmed to decelerate cognitive decline for early Alzheimer's disease patients, a feat that underscores the importance of continual research and development in this challenging therapeutic area.

The Hartwig Piepenbrock-DZNE Prize, awarded every two years since 2011, highlights the relentless pursuit of knowledge in the Alzheimer’s field. It serves as a reminder of the vital research necessary to understand and combat neurodegenerative diseases, a cause championed by Lannfelt throughout his career. The award is named in memory of Hartwig Piepenbrock, whose own struggles with dementia symbolize the urgent need for advancements in therapeutic options.

With the award nearing presentation, anticipation grows regarding the potential for further advancements in drug treatments and diagnostic technologies that could lead to groundbreaking shifts in handling Alzheimer’s and other neurodegenerative diseases. The healthcare community, patients, and their families look forward to the innovations brought forth by diligent researchers like Professor Lannfelt.

BioArctic continues its path as a leading force in biopharmaceutical innovation, driven by the mission to pioneer therapies aimed at altering the trajectory of devastating diseases.

For more information about BioArctic and its initiatives, please visit www.bioarctic.com.